NCT03556228 - Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Head and Neck CarcinomaAdenoid Cystic CarcinomaLung CancerNon-Small Cell Lung CancerBreast CancerPancreatic CancerMesotheliomaThymic CarcinomaCervical CancerOvarian CancerBladder CancerEsophageal CancerUterine CancerSarcomaAny Solid Tumors Progressed After a Prior ImmunotherapyThymomaAppendiceal CancerOlfactory Neuroblastoma

Interventions

DRUG

VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)

Taken orally once daily

Trial Locations (15)

10065

RECRUITING

Weill Cornell Medicine, Cornell University (site 126), New York

17403

RECRUITING

Cancer Care Associates of York (site 206), York

20037

RECRUITING

The George Washington University Cancer Center (site 212), Washington D.C.

33028

RECRUITING

Memorial Cancer Institute at Memorial Healthcare Systems (site 132), Pembroke Pines

33308

RECRUITING

Holy Cross Hospital (site 213), Fort Lauderdale

43537

RECRUITING

Taylor Cancer Research Center (site 204), Maumee

77030

RECRUITING

The University of Texas MD Anderson Cancer Center (site 127), Houston

84106

RECRUITING

Utah Cancer Specialists (site 203), Salt Lake City

87110

RECRUITING

Presbyterian Kaseman Hospital (site 208), Albuquerque

95403

RECRUITING

Providence Medical Foundation (site 209), Santa Rosa

06102

RECRUITING

Hartford Hospital (site 210), Hartford

07631

RECRUITING

Englewood Hospital and Medical Center (site 202), Englewood

07932

RECRUITING

Summit Medical Group (site 205), Florham Park

07962

RECRUITING

Atlantic Health System, Morristown Medical Center (site 124), Morristown

00935

RECRUITING

PanOncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200), San Juan

All Listed Sponsors

lead

VM Oncology, LLC

INDUSTRY